✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Epaned is a drug marketed by Azurity and Silvergate Pharms and is included in two NDAs. There are thirteen patents protecting this drug and one Paragraph IV challenge.
This drug has three patent family members in three countries.
The generic ingredient in EPANED is enalapril maleate. There are twenty-seven drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the enalapril maleate profile page.
A generic version of EPANED was approved as enalapril maleate by HERITAGE PHARMA on August 22nd, 2000.
Summary for EPANED
|Finished Product Suppliers / Packagers:||2|
|Raw Ingredient (Bulk) Api Vendors:||50|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for EPANED|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for EPANED|
|What excipients (inactive ingredients) are in EPANED?||EPANED excipients list|
|DailyMed Link:||EPANED at DailyMed|
Pharmacology for EPANED
EPANED is protected by seventeen US patents.
Patents protecting EPANED
See the table below for patents covering EPANED around the world.
|Country||Patent Number||Title||Estimated Expiration|
|European Patent Office||3429581||FORMULATIONS D'ÉNALAPRIL (ENALAPRIL FORMULATIONS)||See Plans and Pricing|
|Brazil||112018068960||formulações de enalapril||See Plans and Pricing|
|World Intellectual Property Organization (WIPO)||2017161339||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|